Temporal Trends in Adverse Event Costs with Nivolumab + Relatlimab Combination Therapy or Nivolumab Monotherapy for Patients with Unresectable or Metastatic Melanoma

Viviana Garcia-Horton,¹ Zheng-Yi Zhou,² Andriy Moshyk,³ Lisa Rosenblatt,³ Divya Patel,³ Yiqiao Xin,² Qingyuan Wang,² Dana Christensen,¹ Jennell Palaia³

¹Analysis Group, Inc., New York, NY, US; ² Analysis Group, Inc., London, UK; ³Bristol Myers Squibb, Lawrenceville, NJ, US

Introduction

- Melanoma is one of the deadliest malignant cancers in the United States, accounting for approximately 75% of skin cancer deaths despite only representing 4% of skin cancer cases.¹ In 2023, approximately 97,610 people will be diagnosed and 7,990 people are expected to die from melanoma²
- The introduction of novel therapies and immunooncology agents has greatly improved survival outcomes over the last 10 years³
- Lymphocyte-activation gene 3 (LAG-3) and programmed cell death protein 1 (PD-1), two distinct immune checkpoints often co-expressed on tumor-infiltrating lymphocytes (TILs), contribute to tumor-mediated T-cell dysfunction. Nivolumab (NIVO) is an anti-PD-1 antibody that relieves T-cell dysfunction and restores cytotoxic function,⁴ and has been a standard of care for treating unresectable or metastatic melanoma. Relatlimab (RELA) is a human LAG-3 blocking antibody that restores the effector function of dysfunctional T-cells⁵
- RELATIVITY-047 (NCT03470922) investigated NIVO + RELA as a fixed-dose combination therapy in patients with unresectable or metastatic melanoma.⁵ NIVO + RELA was approved by the FDA in 2022⁶
- At a median follow-up of 13.2 months, NIVO + RELA demonstrated superior progression free survival (PFS) versus NIVO (hazard ratio, 0.75; 95% CI, 0.62 to 0.92; P=0.006)⁴
- At a median follow-up of 19.3 months, sustained PFS benefit, clinically meaningful improvement in overall survival (OS), and numerically higher objective response rate (ORR) were observed with NIVO + RELA compared to NIVO (median PFS: 10.2) vs. 4.6 months, hazard ratio [HR]: 0.78 [95% CI: 0.64, 0.94]; median OS: not reached [NR] vs. 34.1 months, HR: 0.80 [95% CI: 0.64, 1.01]; ORR: 43.1% [95% CI: 37.9, 48.4] vs. 32.6% [95% CI: 27.8, 37.7])⁷
- NIVO + RELA showed a manageable safety profile with no new or unexpected safety signals and a positive benefit/risk profile. The impact of treatmentrelated adverse events (TRAEs) on health-related quality of life was similar between the treatment arms, suggesting a perceived treatment tolerance with NIVO + RELA⁸
- To inform decision-making, it is important to fully understand the safety profile of treatment options and the economic burden associated with adverse events (AEs), including temporal patterns and cost drivers

Objectives

- The present study summarized the hospitalization costs of grade 3 or 4 all-cause AEs and TRAEs among treatment naïve patients with unresectable or metastatic melanoma treated with NIVO + RELA or NIVO in RELATIVITY-047 as follows:
- Estimated the per-patient costs within 6, 12, and 24 months, and the entire study period
- Described temporal trends of per-patient per-month (PPPM) costs over the entire study period
- Identified the top drivers of costs over different time periods (i.e., entire study period, and within 1-6, 7-12, 13-24, and 25-35 months)

Methods

Data sources

- median follow-up)⁴
- safety window after ending treatment

AE cost calculation

- period
- between AE start date and date of first exposure to treatment

Statistical analyses

- Temporal trends
- AE cost drivers
- disorders, gastrointestinal disorders, laboratory investigations)

Results

Per-patient AE costs

entire study period (Table 1)

Table 1: Per-patient grade 3 or 4 hospitalization AE costs over each period

	Per-patient A	Per-patient AE cost (USD)	
	NIVO + RELA	NIVO	
All-cause grade 3 or 4 AE costs			
Up to 6 months	\$5,160	\$3,708	
Up to 12 months	\$7,026	\$5,068	
Up to 24 months	\$8,610	\$6,700	
Over the entire study period	\$8,911	\$7,072	
Treatment-related grade 3 or 4 AE costs			
Up to 6 months	\$1,167	\$703	
Up to 12 months	\$1,741	\$1,056	
Up to 24 months	\$2,307	\$1,808	
Over the entire study period	\$2,349	\$1,855	

Abbreviations: AE, adverse event; NIVO, nivolumab; RELA, relatlimab; USD, US Dollars.

• AEs were identified from individual-level patient data (IPD) from the RELATIVITY-047 intention-to-treat (ITT) population (NIVO + RELA: N = 355; NIVO N = 359; October 28, 2021 database lock; 19.3 months

- All grade 3 or 4 all-cause AEs or TRAEs occurring in either treatment arm between treatment initiation date and 30 days after the last dose of study drug (i.e., 30-day treatment-emergent AEs) were included; no minimum threshold was imposed on the AE rates for inclusion into the analyses

- Patients at risk were defined as patients who were still on treatment or within the above 30-day

• Inpatient AE unit costs were identified from the US 2019 Healthcare Cost and Utilization Project (HCUP) National Inpatient Sample (NIS) database⁹ based on International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes, and were inflated to 2021 USD¹⁰ (the most recent price year available within inflation index at the time when this study was conducted)

• The cost for a given AE was calculated by multiplying its unit cost by its frequency within the relevant

• Time to AE, which was used to allocate an AE to its given month, was calculated as the difference

• If the time periods of two or more AEs overlapped (i.e., one AE's start date fell between another AE's start and end date), the cost of the most expensive AE was used to represent all AEs in that period - A sensitivity analysis was conducted by using costs of all overlapping AEs without adjustment

• Per-patient AE costs were calculated by dividing total AE costs by number of patients in each arm

- PPPM AE costs were calculated for each month by dividing the sum of AE costs by the sum of personmonths at risk, and then graphically depicted over the entire study period. A non-parametric local polynomial regression (LOESS) method was used to plot smooth curves

- Per-patient AE costs were summarized for each AE category defined by body system or organ class based on Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (e.g., vascular

- For each specific period, AE costs per category were calculated by dividing the total AE costs for each AE category over the time period by the sum of person-months at risk within that period


- The AE categories associated with the highest costs were identified as the top cost drivers

• NIVO + RELA was associated with higher per-patient costs of all-cause AEs compared to NIVO (\$8,911 vs. \$7,072, cost difference of \$1,839) and TRAEs (\$2,349 vs. \$1,855, cost difference of \$494) over the

Temporal trends in all-cause AE and TRAE costs

- and became more similar through the second and third years
- the remaining period
- remaining period

Figure 1. PPPM grade 3 or 4 AE hospitalization costs among patients in RELATIVITY-047



Top drivers of all-cause AE and TRAE costs

- of total costs) (Figure 2)
- (\$216) for NIVO (58% of total costs) (Figure 2)

Both NIVO + RELA and NIVO followed similar trends of PPPM AE costs

- All-cause AE costs were highest in the first 6 months, decreased during the first year (72% reduction for NIVO + RELA; 82% reduction for NIVO), and plateaued through the second and third years (Figure 1a)


- TRAE costs were much lower initially compared to all-cause AEs, and remained stable throughout the study (Figure 1b) • Average PPPM all-cause AE and TRAE costs were slightly higher for NIVO + RELA than NIVO, especially in the first year,

– All-cause AE: \$825 for NIVO + RELA and \$608 for NIVO in year 1, and \$385 for NIVO + RELA and \$406 for NIVO for

- TRAE: \$211 for NIVO + RELA and \$132 for NIVO in year 1, and \$122 for NIVO + RELA and \$167 for NIVO for the

• Over the entire study period, top all-cause AE cost-driver categories were neoplasms (\$1,236), infections and infestations (\$1,016), and vascular disorders (\$963) for NIVO + RELA, accounting for 36% of total costs; and neoplasms (\$1,374), blood and lymphatic system disorders (\$902), and metabolism and nutrition disorders (\$780) for NIVO (43%

• Over the entire study period, top TRAE cost-driver categories were laboratory investigations (\$461), gastrointestinal disorders (\$264), and endocrine disorders (\$208) for NIVO + RELA, accounting for 40% of costs; and blood and lymphatic system disorders (\$612), skin and subcutaneous tissue disorders (\$244), and laboratory investigations



Sensitivity analysis

Limitations

- costs of these AEs

Conclusions

References

Disclosures

Conflicts of interest: AM, DP, JP, and LR are employees of Bristol Myers Squibb. DC, QW, VGH, YX, and ZZ are employees of Analysis Group, Inc., which received funding from Bristol Myers Squibb. Funding: This study was funded by Bristol Myers Squibb.

Figure 2. Per-patient all-cause and treatment-related grade 3 or 4 AE hospitalization costs (by AE category) over the entire study period among patients in RELATIVITY-047

• The results and conclusions were similar with and without adjustment for overlapping AEs (data not shown)

• Costs associated with grade 1 and 2 AEs and the non-inpatient costs (e.g., outpatient or community services) associated with grade 3 or 4 AEs were not included in this analysis because the standard US unit costs are unavailable in the HCUP NIS data. These events are usually of relatively low-cost impact compared to inpatient costs • This analysis assumed all grade 3 or 4 AEs resulted in hospitalization, which may potentially overestimate the

• The AE cost trends over the study period were similar for the NIVO + RELA and NIVO arms, with slightly higher cost associated with NIVO + RELA (approximately \$500 difference per patient in TRAE costs)

• NIVO + RELA has demonstrated significant improvement in PFS, clinically meaningful improvement in OS, and numerically higher confirmed ORR compared to NIVO monotherapy. Patients had similar health-related quality of life in the NIVO + RELA and NIVO arms. The results of this analysis suggest that these benefits are achieved with minimal incremental economic burden associated with AE management

Copies of this poster are for personal use only and may not be reproduced without written permission of the authors.

^{1.} Davis L, Shalin S, Tackett A. Cancer Biology & Therapy. 2019;20(11):1366-79

^{2.} Facts & Figures 2023. American Cancer Society. 2023.

^{3.} Hassel JC. The Lancet Oncology. 2019;20(9):1187-9.

^{4.} Tawbi HA, Schadendorf D, Lipson EJ, et al. New England Journal of Medicine. 2022;386(1):24-34.

^{5.} Long GV, Stephen Hodi F, Lipson EJ, et al. NEJM Evidence. 2023; 2(4).

^{6.} OPDUALAG[™] (nivolumab and relatlimab-rmbw) injection, for intravenous use. US Food and Drug Administration. 2022 7. Long GV, Hodi FS, Lipson EJ, et al. *Journal of Clinical Oncology*. 2022;40:36_suppl-360385

^{8.} Schadendorf D, Tawbi H, Lipson EJ, et al. European Journal of Cancer. 2023. In press. DOI:https://doi.org/10.1016/j.ejca.2023.03.014

^{9.} HCUP Overview. Healthcare Cost and Utilization Project (HCUP). Quality AfHRa. 2022.

^{10.} Household consumption expenditures, Health care. US Bureau of Economic Analysis. 2022.